Article Data

  • Views 382
  • Dowloads 125

Case Reports

Open Access

Efficacy of multimodality therapy for patients with large-sized locally advanced breast cancer - a retrospective analysis of 17 cases

  • J. Song1
  • J. M1
  • X. Qi1,*,

1Department of Galactophore, The Seventh Medicanl Center of PLA general Hosptital, Beijing (China)

DOI: 10.31083/j.ejgo.2020.01.4868 Vol.41,Issue 1,February 2020 pp.116-120

Published: 15 February 2020

*Corresponding Author(s): X. Qi E-mail:


The objective of this study was to explore the clinical significance of multimodality therapy for huge-sized locally advanced breast cancer (LABC) in a retrospective analysis of 17 patients with large-sized locally advanced breast cancer. The mean tumor size was 11.5×10.1× cm. Among these 17 patients, three (17.6%) cases developed clinical evidence of distant metastases (liver, lung, bone, etc.), ten cases (58.8%) had skin ulcers, and discharges with a peculiar smell. The patients underwent TEC/AT chemotherapy, interventional therapy, and Ad-p53 gene therapy. All treatments were well-tolerated and 15 (88.2%) cases of the patient underwent standard or modified radical mastectomy successfully. The other two patients, who di not undergo surgical treatment because of metastases and other reasons, were treated with endocrine therapy. Until now, the average survival time has reached 31.5 months. In treating large-sized locally advanced breast cancer, multimodal therapies are able to diminish the burthen of the tumor, lower the clinical stage, and increase resection rate of cancer, thus improving survival rates and quality of life for patients.


LABC; Multimodality therapy; Ad-p53 gene therapy; Interventional therapy.

Cite and Share

J. Song,J. M,X. Qi. Efficacy of multimodality therapy for patients with large-sized locally advanced breast cancer - a retrospective analysis of 17 cases. European Journal of Gynaecological Oncology. 2020. 41(1);116-120.


[1] Tryfonidis K., Senkus E., Cardoso M.J., Cardoso F.: “Management of locally advanced breast cancer—perspectives and future directions American Joint Commission on Cancer”. Nat. Rev. Clin. Oncol., 2015, 12, 147.

[2] National Comprehensive Cancer Network (NCCN): “NCCN Clinical Practice Guidelines in Oncology: Breast Cancer”. Fort Washington, PA: NCCN; 2015. Ver. 3.2015. Available at: http://www.nccn. org/professionals/physician_gls/pdf/breast.pdf

[3] Shimamoto H., Takizawa K., Ogawa Y., Yoshimatsu M., Yagihashi K., Okazaki H., et al.: “Clinical efficacy and value of redistributed subclavian arterial infusion chemotherapy for locally advanced breast cancer”. Jpn. J. Radiol., 2011, 29, 236.

[4] Santoro G., Avossa M., Della Corte M.: “Radiofrequency thermoablation in locally advanced breast cancer”. Breast, 2012, 21, 601.

[5] Debled M., MacGrogan G., Breton-Callu C., Ferron S., Hurtevent G., Fournier M., et al.: “ Surgery following NAC for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude”. Eur. J. Cancer, 2015, 51, 697.

[6] Emiroglu M., Sert I., Karaali C., Aksoy S.O., Ugurlu L., Aydın C.: “The effectiveness of simultaneous oncoplastic breast surgery in patients with locally advanced breast cancer”. Breast Cancer, 2016, 23, 463.

[7] Xie Y.S., Zhang Y.H., Liu S.P., Liu S.Q., Peng C.W., Wu L., et al.: “Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study”. Oncol. Rep., 2010, 24, 1613.

[8] Nakajima S., Niizeki H., Tada M., Nakagawa K., Kondo S., Okada F., Kobayashi M.: Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231”. Oncol. Rep., 2009, 22, 143.

[9] Qi X., Chang Z., Song J., Gao G., Shen Z.: “Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin”. Anticancer Drugs, 2011, 22, 556.

[10] Simos D., Clemons M., Ginsburg O.M., Jacobs C.: “Definition and consequences of locally advanced breast cancer”. Curr. Opin. Support Palliat. Care, 2014, 8, 33.

[11] Perez E.A., Foo M.L., Fulmer J.T.: “Management of locally advanced breast cancer”. Oncology (Williston Park), 1997, 11, 9.

[12] Fei F., Messina C., Slaets L., Chakiba C., Cameron D., Bogaerts J., Bonnefoi H.: “Tumor size is the only predictive factor of distant recurrence after pathological complete response to NAC in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial”. Eur. J. Cancer, 2015, 51, 301.

[13] Chan A., Willsher P.C., Hastrich D.J., Anderson J., Barham T., Latham B., et al.: “Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer”. Asia Pac, J. Clin. Oncol., 2012, 8, 62.

[14] Ooe A., Takahara S., Sumiyoshi K., Yamamoto H., Kawai J., Shiba E.: “Relationship between intrinsic subtypes and tumor responses to NAC in patients with locally advanced breast cancer”. Breast Dis., 2012, 34, 9.

[15] Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G., et al.: “Phase III Open-Label Randomized Study of Eribulin esylate Versus Capecitabine in Patients With Locally advanced or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane”. J. Clin. Oncol., 2015, 33, 594.

[16] Cristofanilli M., Krishnamurthy S., Guerra L., Broglio K., Arun B., Booser D.J., et al.: “A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach”. Cancer, 2006, 107, 935.

[17] He S.Z., Qi X.D., Zhang X.M., Wang Y.: “Experimental study of adenovirus-mediated p53 gene on the reversal of multidrug resistance in breast cancer”. Zhonghua Yi Xue Za Zhi, 2007, 87, 2935.

[18] Wang X., Gan C., Li H., Wei Y., Zhu D., Yang G., et al.: “Main complications and results of treatment with intra-arterial infusion chemotherapy through the subclavian and thoracic arteries for locally advanced breast cancer”. Mol. Clin. Oncol., 2013, 1, 745.

[19] Jin H.Y., He W., Liu Q., Wang X.F., Liu Y.F., Wei Z.X.: “Efficacy of intra-arterial NAC through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer”. Neoplasma, 2016, 63, 607.

[20] Wink C.J., Woensdregt K., Nieuwenhuijzen G.A., van der Sangen M.J., Hutschemaekers S., Roukema J.A., et al.: “Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer”. Ann. Surg. Oncol., 2012, 19, 1185.

[21] Nomiya T., Akamatsu H., Harada M., Ota I., Hagiwara Y., Ichikawa M., et al.: “Modified simultaneous integrated boost radiotherapy for unresectable locally advanced breast cancer: preliminary results of a prospective clinical trial”. Clin. Breast Cancer, 2015, 15, 161.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time